## DHR: Danaher Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.0% below STRENGTH zone (3.0-6.0%); PEG 1.98 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($228.17)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 1)

**1. Danaher’s Push Into Higher‑Margin Life Sciences Might Change The Case For Investing In DHR**
- Source: Simply Wall Street | 20260105T132509 | Somewhat-Bullish | Relevance: 100%
- Danaher is strategically refocusing its portfolio on higher-margin life sciences and diagnostics by divesting lower-priority units to strengthen its position as a healthcare and biotech tools provider. This shift aims to improve its business mix and profitability, with projections of $29.2 billion revenue and $5.7 billion earnings by 2028. However, potential prolonged weakness in early-stage biotech funding could still pose a risk to its genomics and instrument demand.

**2. Greenleaf Trust Has $15.47 Million Stock Holdings in Danaher Corporation $DHR**
- Source: MarketBeat | 20260106T123754 | Somewhat-Bullish | Relevance: 100%
- Greenleaf Trust reduced its stake in Danaher Corporation by 7.8% in the third quarter, now holding 78,048 shares valued at $15.47 million. Despite this, institutional investors own 79.05% of the stock, and analysts maintain a "Moderate Buy" rating with an average price target of $249.50. Company insiders have been net sellers, offloading 30,248 shares worth approximately $6.61 million in the last 90 days.

**3. Danaher to Present at J.P. Morgan Healthcare Conference**
- Source: Yahoo Finance Singapore | 20260105T211500 | Neutral | Relevance: 100%
- Danaher Corporation announced that its President and CEO, Rainer M. Blair, will present at the J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 11:15 a.m. PT. The presentation will be webcast live on Danaher's website. Danaher is a global life sciences and diagnostics innovator focused on improving human health through scientific and technological advancements.

**4. Evercore ISI Adjusts Price Target on Danaher to $250 From $245, Maintains Outperform Rating**
- Source: marketscreener.com | 20260105T171500 | Somewhat-Bullish | Relevance: 100%
- Evercore ISI has increased its price target for Danaher Corporation (DHR) to $250 from $245, reiterating an Outperform rating. This adjustment reflects a positive outlook for the company's financial performance. Danaher Corporation specializes in diagnostic, life sciences, and biotechnology equipment.

**5. Railway Pension Investments Ltd Boosts Stake in Danaher Corporation $DHR**
- Source: MarketBeat | 20260105T122319 | Bullish | Relevance: 100%
- Railway Pension Investments Ltd significantly increased its stake in Danaher Corporation (NYSE:DHR) by 148.4% in the third quarter of 2025, now holding 689,899 shares valued at $136.8 million. Danaher reported strong Q3 earnings, beating analyst estimates with EPS of $1.89 and revenue of $6.05 billion, and analysts maintain a "Moderate Buy" rating with an average target price of $249.29. Despite insider sales totaling approximately $6.61 million over the past three months, institutional investors own 79.05% of the stock.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Guggenheim | $275 | $250 | +10% |
| 2025-12-15 | Wells Fargo | $240 | $230 | +4% |
| 2025-12-09 | Goldman Sachs | $265 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Guggenheim | main | Buy |
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-09 | Goldman Sachs | init | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 10 ($0.79M) |
| Sells | 9 ($100.22M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 8.6% (+0.2%)
- Blackrock Inc.: 7.4% (+0.1%)
- JPMORGAN CHASE & CO: 5.3% (+404.7%)
- State Street Corpora: 3.9% (-0.3%)
- Capital Internationa: 2.4% (+1.9%)

### Key Risks

1. Heavy insider selling: $100M sold (9 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +1.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.98 elevated, pricing in significant growth expectations. Forward P/E 28.1x stretched relative to 9% growth. Balance sheet: $1.4B free cash flow. Analyst sentiment positive (2 raises, avg +7%, $262 target (+11%)). Insider selling cluster ($100.2M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $169.4B |
| Beta | 0.93 |
| 52W Range | $171.00 - $258.23 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.98 |
| Forward P/E | 28.1 |
| Current P/E | 30.7 |
| YoY Growth | 9.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 0.9% to 2.0% (+1.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.0pp (needs >3.0% for momentum thesis). MRS_5 at 1.1% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.96% (CS: 60) | Neutral |
| RSI_14 | 65.8 | Neutral |
| MACD Histogram | 0.45 | Bullish |
| vs SMA20 | 1.035x | Above |
| vs SMA50 | 1.057x | Above |
| vs SMA200 | 1.155x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $236.73
- **Stop Loss:** $228.17 (3.6% risk)
- **Target:** $245.29 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 154
- **Position Value:** $36,456.42
- **Portfolio %:** 36.46%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-01-28 (Est: $2.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.72 | $1.89 | +9.8% |
| 2025Q2 | $1.64 | $1.80 | +9.5% |
| 2025Q1 | $1.64 | $1.88 | +14.4% |
| 2024Q4 | $2.16 | $2.14 | -1.1% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*